Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

20132,509 citationsJournal Articlebronze Open Access

Authors

William B. White · University of Connecticut

Christopher P. Cannon · Harvard University

Simon Heller · University of Sheffield

Steven E. Nissen · Cleveland Clinic

Richard M. Bergenstal · Park Nicollet Clinic

George L. Bakris · University of Chicago

Alfonso T. Perez ·

Abstract

Among patients with type 2 diabetes who had had a recent acute coronary syndrome, the rates of major adverse cardiovascular events were not increased with the DPP-4 inhibitor alogliptin as compared with placebo. (Funded by Takeda Development Center Americas; EXAMINE ClinicalTrials.gov number, NCT00968708.).

Topics & Keywords

Diabetes Treatment and Management Diabetes Management and Research Cardiovascular Function and Risk Factors

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 369, Issue 14, pp. 1327-1335

DOI: 10.1056/nejmoa1305889

Field-Weighted Citation Impact: 173.18